Skip to main content
. Author manuscript; available in PMC: 2015 Jun 30.
Published in final edited form as: J Clin Oncol. 2008 May 1;26(13):2186–2191. doi: 10.1200/JCO.2007.14.3552

Figure 1. Event-free survival (EFS) estimates of patients treated on ALinC 16 and their relation to TEL gene status.

Figure 1

(A) EFS estimates of patients with TEL rearrangements (R-TEL) compared with those of patients with germline TEL (G-TEL). (B) EFS estimates of patients with NCI standard-risk ALL shown in relation to TEL status. (C) EFS estimates of patients with NCI high-risk ALL shown in relation to TEL status.